Shares of Sophiris Bio Inc (NASDAQ:SPHS) dropped 3.8% during trading on Wednesday . The stock traded as low as $3.65 and last traded at $3.85, with a volume of 2,526,601 shares trading hands. The stock had previously closed at $4.00.

SPHS has been the subject of several recent analyst reports. Maxim Group reissued a “buy” rating and issued a $4.00 price target on shares of Sophiris Bio in a report on Thursday, March 24th. Echelon Wealth Partners reissued a “buy” rating and issued a $5.00 price target on shares of Sophiris Bio in a report on Friday, June 10th.

The stock has a 50-day moving average of $1.99 and a 200 day moving average of $1.66. The stock’s market capitalization is $79.31 million.

Sophiris Bio (NASDAQ:SPHS) last posted its earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.06. Equities analysts predict that Sophiris Bio Inc will post ($0.73) EPS for the current year.

Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.